Results 71 to 80 of about 38,655 (210)

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.

JAMA dermatology, 2020
Importance The association between the use of medications and the development of bullous pemphigoid (BP) is unclear. Objective To assess the associations between previous exposure to certain medications and BP. Data Sources For this systematic review
Sian-De Liu, Wei-Ti Chen, C. Chi
semanticscholar   +1 more source

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Maike M. Holtsche, Nina van Beek, Christoph M. Hammers, Artem Vorobyev, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt   +7 more
wiley   +1 more source

Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population‐based cohort study *

British Journal of Dermatology, 2020
A rising incidence and high mortality were found for bullous pemphigoid (BP) over a decade ago in the UK. Updated estimates of its epidemiology are required to understand the healthcare needs of an ageing population.
M. Persson, K. Harman, Y. Vinogradova, S. Langan, J. Hippisley-Cox, K. Thomas, S. Gran   +6 more
semanticscholar   +1 more source

Wells syndrome: clinical findings and management in a large cohort of 48 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives: Wells syndrome (WS) is a rare inflammatory skin disorder typically characterized by erythematous, edematous, and pruritic plaques. Despite its distinct histopathological features, WS remains an underdiagnosed disease due to its variable clinical presentations and overlap with other dermatological conditions.
Marco Adriano Chessa, Silvia Robuffo, Tullio Brunetti, Luca Rapparini, Bianca Maria Piraccini, Cosimo Misciali, Beatrice Raone, Iria Neri, Federica Filippi   +8 more
wiley   +1 more source

Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment

Dermatology Practical & Conceptual, 2020
Autoimmune bullous disorders are a heterogeneous spectrum of skin disorders characterized by the production of autoantibodies against adhesion molecules of the skin. The 2 major groups of diseases are “pemphigus diseases” and “autoimmune bullous diseases
V. Di Lernia, D. Casanova, M. Goldust, C. Ricci   +3 more
semanticscholar   +1 more source

A Case of Palmoplantar Vesiculobullous Lesions

JEADV Clinical Practice, EarlyView.
Ali Abid, Kelvin Truong, Jing Jing Li, Artiene Tatian   +3 more
wiley   +1 more source

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients

Acta Dermato-Venereologica
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes.
Dana Shalmon, Efrat Bar-Ilan, Alon Peled, Shamir Geller, Jonathan Bar, Naama Schwartz, Eli Sprecher, Mor Pavlovsky   +7 more
doaj   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source